Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062

European Journal of Cancer

Volumn 47, Issue 15, 2011, Pages 2322-2330

  O'Brien, Mary E R ^a   Konopa, Krzystof ^b   Lorigan, Paul ^c   Bosquee, Lionel ^d   Marshall, Ernest ^e   Bustin, Frederique ^f   Margerit, Sabine ^g   Fink, Christian ^h   Stigt, Jos A ⁱ   Dingemans, Anne Marie C ^j   Hasan, Baktiar ^g   Van Meerbeeck, Jan ^k   Baas, Paul ^l  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^f Centre Hospitalier Regional de La Citadelle   (Belgium)

^g EORTC DATA CENTER   (Belgium)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ ISALA HOSPITAL   (Netherlands)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

Amrubicin; Small cell lung cancer; Survival; Toxicity

Indexed keywords

AMRUBICIN; ANTIBIOTIC AGENT; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR;

ACUTE RESPIRATORY FAILURE; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; DIARRHEA; DRUG ACTIVITY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LUNG FIBROSIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053364022     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.05.020     Document Type: Article

References (23)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 4 2010 765 781
2. S. Lowenbraun, A. Bartolucci, and R.V. Smalley The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma Cancer 44 2 1979 406 413 (Pubitemid 10220121)
3. S. Sundstrom, R.M. Bremnes, and S. Kaasa Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up J Clin Oncol 20 24 2002 4665 4672 (Pubitemid 36025283)
4. S. Popat, and M. O'Brien Chemotherapy strategies in the treatment of small cell lung cancer Anti-Cancer Drugs 16 2005 361 372 (Pubitemid 40434602)
5. M. Puglisi, S. Dolly, and A. Faria Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 102 4 2010 629 638 (Epub 2010 Jan 26. Review)
6. A. Rossi, M.C. Garassino, and M. Cinquini Maintenance or consolidation therapy in small-cell lung cancer: a systemic review and meta-analysis Lung Cancer 70 2 2010 119 128
7. J.P. Steele Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation Semin Oncol 28 3 Suppl. 10 2001 15 18 (Pubitemid 32757655)
8. J. von Pawel, J.H. Schiller, and F.A. Shepherd Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 2 1999 658 667 (Pubitemid 29075255)
9. N. Hanna, P.A. Bunn Jr, and C. Langer Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage small cell lung cancer J Clin Oncol 24 13 2006 2038 2043 (Pubitemid 46622112)
10. H.B. Niell, J.E. Herndon, and A.A. Miller Final report of a randomized phase III Intergroup trial of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC) Lung Cancer 41 Suppl. 2 2003 S81
11. D. Mavroudis, E. Papadakis, and M. Veslemes A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer Ann Oncol 12 4 2001 463 470 (Pubitemid 32472099)
12. M. Reck, J. von Pawel, and H.N. Macha Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer J Natl Cancer Inst 95 15 2003 1118 1127 (Pubitemid 37045390)
13. I.K. Demedts, K.Y. Vermaelen, and J.P. van Meerbeeck Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Eur Respir J 35 1 2010 202 215 Review
14. S.M. Lee, L.E. James, and V. Mohammed-Ali A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC) Proc Am Soc Clin Oncol 21 2002 313a (abstract 1251)
15. S. Morisada, Y. Yanagi, T. Noguchi, Y. Kashiwazaki, and M. Fukui Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts Jpn J Cancer Res 80 1 1989 69 76 (Pubitemid 20027201)
16. M. Hanada, S. Mizuno, and A. Fukushima A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex Jpn J Cancer Res 89 11 1998 1229 1238 (Pubitemid 29008005)
17. T. Noguchi, S. Ichii, and S. Morisada Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin Jpn J Cancer Res 89 10 1998 1061 1066 (Pubitemid 28544783)
18. T. Yana, S. Negoro, and M. Takada Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study Invest New Drugs 25 3 2006 253 258
19. Y. Ohe, S. Negoro, and K. Matsui Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer Ann Oncol 16 3 2005 430 436 (Pubitemid 40458320)
20. S. Davis, K.E. Stanley, R. Yesner, D.T. Kuang, and J.F. Morris Small-cell carcinoma of the lung-survival according to histologic subtype: a Veterans Administration Lung Group Study Cancer 47 7 1981 1863 1866 (Pubitemid 11145846)
21. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 2000 205 216 (Pubitemid 30099779)
22. M.E.R. O'Brien, T. Ciuleanu, and H. Tsekoy An open-label, multicenter, randomized, phase III comparator study of supportive alone or in combination with oral topotecan in patients with relapsed small-cell lung cancer J Clin Oncol 24 34 2006 5441 5447 (Pubitemid 46623178)
23. S. Sundstrom, R.M. Bremnes, S. Kaasa, U. Aasebo, and S. Aamdal Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen) Lung Cancer 48 2005 251 261